Adenosine receptor signaling in vitro and in vivo
Identifieur interne : 001B13 ( Main/Exploration ); précédent : 001B12; suivant : 001B14Adenosine receptor signaling in vitro and in vivo
Auteurs : Bertil B. Fredholm [Suède] ; Giulia Arslan [Suède] ; Linda Halldner [Suède] ; Björn Kull [Suède] ; Gunnar Schulte [Suède] ; Ulrika Dén [Suède] ; Per Svenningsson [Suède]Source :
- Drug Development Research [ 0272-4391 ] ; 2001-01.
English descriptors
- KwdEn :
Abstract
This overview will focus on recent data from our laboratory. The four cloned human adenosine receptors stably transfected into Chinese hamster ovary cells were studied with respect to signaling via cyclic AMP and mitogen‐activated protein (MAP) kinases. Adenosine acted as a full agonist at all the adenosine receptors when increases (A2A or A2B receptors) or decreases (A1 and A3 receptors) in cyclic AMP accumulation were studied. Adenosine was approximately equipotent at A1, A2A, and A3 receptors, but approximately 50 times higher concentrations were needed at A2B receptors. The potency of adenosine was such that levels encountered under basal physiological conditions (30–300 nM) were sufficient to activate all but the A2B receptors. Inosine was a low‐efficacy agonist at A1 and A3 receptors but was inactive at A2A and A2B receptors. Thus, adenosine is the most important agonist and the only one at A2A and A2B receptors. When MAP kinase signaling was examined, adenosine was equipotent at all the four receptors, and significant activation was noted at 100 nM adenosine. The potency of adenosine is dependent not only on the type of receptor but also on receptor number. Thus, high potency of adenosine is seen only where the receptor is expressed abundantly. These and other results are reviewed and discussed in relation to agonist and antagonist effects in vivo. In particular, we summarize recent data that show that adenosine tonically activates A2A receptors in the basal ganglia. Some aspects of the use of adenosine A2A receptor antagonists in the treatment of Parkinson disease also are highlighted. Drug Dev. Res. 52:274–282, 2001. © 2001 Wiley‐Liss, Inc.
Url:
DOI: 10.1002/ddr.1124
Affiliations:
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Adenosine receptor signaling in vitro and in vivo</title><author><name sortKey="Fredholm, Bertil B" sort="Fredholm, Bertil B" uniqKey="Fredholm B" first="Bertil B." last="Fredholm">Bertil B. Fredholm</name></author><author><name sortKey="Arslan, Giulia" sort="Arslan, Giulia" uniqKey="Arslan G" first="Giulia" last="Arslan">Giulia Arslan</name></author><author><name sortKey="Halldner, Linda" sort="Halldner, Linda" uniqKey="Halldner L" first="Linda" last="Halldner">Linda Halldner</name></author><author><name sortKey="Kull, Bjorn" sort="Kull, Bjorn" uniqKey="Kull B" first="Björn" last="Kull">Björn Kull</name></author><author><name sortKey="Schulte, Gunnar" sort="Schulte, Gunnar" uniqKey="Schulte G" first="Gunnar" last="Schulte">Gunnar Schulte</name></author><author><name sortKey=" Den, Ulrika" sort=" Den, Ulrika" uniqKey=" Den U" first="Ulrika" last=" Dén">Ulrika Dén</name></author><author><name sortKey="Svenningsson, Per" sort="Svenningsson, Per" uniqKey="Svenningsson P" first="Per" last="Svenningsson">Per Svenningsson</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:2163A23A7BC12BEF231915F424741FFF48C87D22</idno><date when="2001" year="2001">2001</date><idno type="doi">10.1002/ddr.1124</idno><idno type="url">https://api.istex.fr/document/2163A23A7BC12BEF231915F424741FFF48C87D22/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002144</idno><idno type="wicri:Area/Main/Curation">001E37</idno><idno type="wicri:Area/Main/Exploration">001B13</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Adenosine receptor signaling in vitro and in vivo</title><author><name sortKey="Fredholm, Bertil B" sort="Fredholm, Bertil B" uniqKey="Fredholm B" first="Bertil B." last="Fredholm">Bertil B. Fredholm</name><affiliation wicri:level="3"><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm</wicri:regionArea><placeName><settlement type="city">Stockholm</settlement><region nuts="2">Svealand</region></placeName></affiliation></author><author><name sortKey="Arslan, Giulia" sort="Arslan, Giulia" uniqKey="Arslan G" first="Giulia" last="Arslan">Giulia Arslan</name><affiliation wicri:level="3"><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm</wicri:regionArea><placeName><settlement type="city">Stockholm</settlement><region nuts="2">Svealand</region></placeName></affiliation></author><author><name sortKey="Halldner, Linda" sort="Halldner, Linda" uniqKey="Halldner L" first="Linda" last="Halldner">Linda Halldner</name><affiliation wicri:level="3"><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm</wicri:regionArea><placeName><settlement type="city">Stockholm</settlement><region nuts="2">Svealand</region></placeName></affiliation></author><author><name sortKey="Kull, Bjorn" sort="Kull, Bjorn" uniqKey="Kull B" first="Björn" last="Kull">Björn Kull</name><affiliation wicri:level="3"><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm</wicri:regionArea><placeName><settlement type="city">Stockholm</settlement><region nuts="2">Svealand</region></placeName></affiliation></author><author><name sortKey="Schulte, Gunnar" sort="Schulte, Gunnar" uniqKey="Schulte G" first="Gunnar" last="Schulte">Gunnar Schulte</name><affiliation wicri:level="3"><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm</wicri:regionArea><placeName><settlement type="city">Stockholm</settlement><region nuts="2">Svealand</region></placeName></affiliation></author><author><name sortKey=" Den, Ulrika" sort=" Den, Ulrika" uniqKey=" Den U" first="Ulrika" last=" Dén">Ulrika Dén</name><affiliation wicri:level="3"><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm</wicri:regionArea><placeName><settlement type="city">Stockholm</settlement><region nuts="2">Svealand</region></placeName></affiliation></author><author><name sortKey="Svenningsson, Per" sort="Svenningsson, Per" uniqKey="Svenningsson P" first="Per" last="Svenningsson">Per Svenningsson</name><affiliation wicri:level="3"><country xml:lang="fr">Suède</country><wicri:regionArea>Department of Physiology and Pharmacology, Karolinska Institutet, Stockholm</wicri:regionArea><placeName><settlement type="city">Stockholm</settlement><region nuts="2">Svealand</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Drug Development Research</title><title level="j" type="abbrev">Drug Dev. Res.</title><idno type="ISSN">0272-4391</idno><idno type="eISSN">1098-2299</idno><imprint><publisher>John Wiley & Sons, Inc.</publisher><pubPlace>New York</pubPlace><date type="published" when="2001-01">2001-01</date><biblScope unit="volume">52</biblScope><biblScope unit="issue">1‐2</biblScope><biblScope unit="page" from="274">274</biblScope><biblScope unit="page" to="282">282</biblScope></imprint><idno type="ISSN">0272-4391</idno></series><idno type="istex">2163A23A7BC12BEF231915F424741FFF48C87D22</idno><idno type="DOI">10.1002/ddr.1124</idno><idno type="ArticleID">DDR1124</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0272-4391</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>G protein</term><term>Parkinson disease</term><term>adenosine receptor</term><term>cyclic AMP, mitogen‐activated protein kinase</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">This overview will focus on recent data from our laboratory. The four cloned human adenosine receptors stably transfected into Chinese hamster ovary cells were studied with respect to signaling via cyclic AMP and mitogen‐activated protein (MAP) kinases. Adenosine acted as a full agonist at all the adenosine receptors when increases (A2A or A2B receptors) or decreases (A1 and A3 receptors) in cyclic AMP accumulation were studied. Adenosine was approximately equipotent at A1, A2A, and A3 receptors, but approximately 50 times higher concentrations were needed at A2B receptors. The potency of adenosine was such that levels encountered under basal physiological conditions (30–300 nM) were sufficient to activate all but the A2B receptors. Inosine was a low‐efficacy agonist at A1 and A3 receptors but was inactive at A2A and A2B receptors. Thus, adenosine is the most important agonist and the only one at A2A and A2B receptors. When MAP kinase signaling was examined, adenosine was equipotent at all the four receptors, and significant activation was noted at 100 nM adenosine. The potency of adenosine is dependent not only on the type of receptor but also on receptor number. Thus, high potency of adenosine is seen only where the receptor is expressed abundantly. These and other results are reviewed and discussed in relation to agonist and antagonist effects in vivo. In particular, we summarize recent data that show that adenosine tonically activates A2A receptors in the basal ganglia. Some aspects of the use of adenosine A2A receptor antagonists in the treatment of Parkinson disease also are highlighted. Drug Dev. Res. 52:274–282, 2001. © 2001 Wiley‐Liss, Inc.</div></front></TEI><affiliations><list><country><li>Suède</li></country><region><li>Svealand</li></region><settlement><li>Stockholm</li></settlement></list><tree><country name="Suède"><region name="Svealand"><name sortKey="Fredholm, Bertil B" sort="Fredholm, Bertil B" uniqKey="Fredholm B" first="Bertil B." last="Fredholm">Bertil B. Fredholm</name></region><name sortKey=" Den, Ulrika" sort=" Den, Ulrika" uniqKey=" Den U" first="Ulrika" last=" Dén">Ulrika Dén</name><name sortKey="Arslan, Giulia" sort="Arslan, Giulia" uniqKey="Arslan G" first="Giulia" last="Arslan">Giulia Arslan</name><name sortKey="Halldner, Linda" sort="Halldner, Linda" uniqKey="Halldner L" first="Linda" last="Halldner">Linda Halldner</name><name sortKey="Kull, Bjorn" sort="Kull, Bjorn" uniqKey="Kull B" first="Björn" last="Kull">Björn Kull</name><name sortKey="Schulte, Gunnar" sort="Schulte, Gunnar" uniqKey="Schulte G" first="Gunnar" last="Schulte">Gunnar Schulte</name><name sortKey="Svenningsson, Per" sort="Svenningsson, Per" uniqKey="Svenningsson P" first="Per" last="Svenningsson">Per Svenningsson</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B13 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001B13 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:2163A23A7BC12BEF231915F424741FFF48C87D22
|texte= Adenosine receptor signaling in vitro and in vivo
}}
| This area was generated with Dilib version V0.6.23. |  |